GPP846

GPP846 is a small molecule drug candidate developed by Gene PreDiT for the treatment of obesity. It functions as an agonist of the 5-hydroxytryptamine receptor 2C (5-HT2C), which is identified by the company as target GP0044. GPP846 is developed as part of a personalized medicine strategy, where patients are screened using Gene PreDiT's proprietary diagnostic tools to identify specific genetic markers (such as SNPs in the HTR2C gene) that predict a positive therapeutic response. This approach is intended to optimize weight loss outcomes and minimize side effects by targeting the drug to a genetically defined subpopulation. The candidate has reached Phase 2 clinical development.